Virion Incorporation of the Herpes Simplex Virus Type 1 Tegument Protein VP22 Occurs via Glycoprotein E-Specific Recruitment to the Late Secretory Pathway by Stylianou, J et al.
JOURNAL OF VIROLOGY, May 2009, p. 5204–5218 Vol. 83, No. 10
0022-538X/09/$08.000 doi:10.1128/JVI.00069-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Virion Incorporation of the Herpes Simplex Virus Type 1 Tegument
Protein VP22 Occurs via Glycoprotein E-Specific Recruitment
to the Late Secretory Pathway
Julianna Stylianou,1† Kevin Maringer,1† Rachelle Cook,2 Emmanuelle Bernard,2 and Gillian Elliott1,2*
Department of Virology, Faculty of Medicine, Imperial College London, London, United Kingdom,1 and
Marie Curie Research Institute, Oxted, Surrey, United Kingdom2
Received 12 January 2009/Accepted 26 February 2009
The mechanism by which herpesviruses acquire their tegument is not yet clear. One model is that outer
tegument proteins are recruited by the cytoplasmic tails of viral glycoproteins. In the case of herpes simplex
virus tegument protein VP22, interactions with the glycoproteins gE and gD have been shown. We have
previously shown that the C-terminal half of VP22 contains the necessary signal for assembly into the virus.
Here, we show that during infection VP22 interacts with gE and gM, as well as its tegument partner VP16.
However, by using a range of techniques we were unable to demonstrate VP22 binding to gD. By using pulldown
assays, we show that while the cytoplasmic tails of both gE and gM interact with VP22, only gE interacts
efficiently with the C-terminal packaging domain of VP22. Furthermore, gE but not gM can recruit VP22 to the
Golgi/trans-Golgi network region of the cell in the absence of other virus proteins. To examine the role of the
gE-VP22 interaction in infection, we constructed a recombinant virus expressing a mutant VP22 protein with
a 14-residue deletion that is unable to bind gE (gEbind). Coimmunoprecipitation assays confirmed that this
variant of VP22 was unable to complex with gE. Moreover, VP22 was no longer recruited to its characteristic
cytoplasmic trafficking complexes but exhibited a diffuse localization. Importantly, packaging of this variant
into virions was abrogated. The mutant virus exhibited poor growth in epithelial cells, similar to the defect we
have observed for a VP22 knockout virus. These results suggest that deletion of just 14 residues from the VP22
protein is sufficient to inhibit binding to gE and hence recruitment to the viral envelope and assembly into the
virus, resulting in a growth phenotype equivalent to that produced by deleting the entire reading frame.
The herpesvirus tegument is the virion compartment located
between the DNA-containing capsid and the virus envelope
(6). Although it is well defined that the viral capsid assembles
in the nucleus (37, 38) and the viral envelope is acquired from
cellular membranes (3, 24), the mechanism of tegument pro-
tein acquisition is still to be established. At least 20 virus-
encoded components are recruited into the herpes simplex
virus type 1 (HSV-1) tegument (32), and there is increasing
evidence to suggest that subsets of these proteins may be
added as assembly progresses along the maturation pathway
(28). To ensure efficient incorporation, it is likely that individ-
ual tegument proteins are specifically targeted to their cellular
site of recruitment. Such targeting could involve interaction
with a viral partner, a cellular partner, or both. A clearer
understanding of how individual tegument proteins are ac-
quired by newly assembling virions will help to define the
herpesvirus assembly pathway.
A number of protein-protein interactions between individual
tegument proteins (13, 40, 42), and between tegument proteins
and glycoproteins (19, 20, 22, 32), have been described that
may provide useful insight into the assembly process. In par-
ticular, the interaction of tegument proteins with the cytoplas-
mic tails of virus glycoproteins provides an attractive mecha-
nism for the virion recruitment of at least the outer
components of the tegument. In the case of VP22, the homo-
logues from pseudorabies virus (PRV) and HSV-1 have been
shown to interact with the cytoplasmic tail of gE (19, 20, 32).
However, the role of this interaction in virus infection has not
yet been clearly defined and the fact that additional glycopro-
tein interactions have been described, with gM in the case of
PRV and gD in the case of HSV-1, may point to potential
redundancy in the mechanism of VP22 packaging (4, 19, 20).
In addition, we and others have previously shown that HSV-1
VP22 interacts directly with a second tegument protein,
namely, VP16 (13, 33), an interaction that could provide an
alternative route for VP22 to enter the virion. In a previous
study, we concluded that the region of VP22 containing its
VP16 interaction domain was required but not sufficient for
optimal VP22 packaging into the assembling virion, with an
additional C-terminal determinant also involved (23). We also
demonstrated that the same region of VP22 that was required
for virion packaging was essential to target the protein to its
characteristic cytoplasmic trafficking complexes, suggesting
that these specific sites may be the location in the cell for VP22
assembly into the virion (23). Since that study, O’Regan and
coworkers have reported that the C-terminal half of HSV-1 VP22
also contains the binding site for gE (32), providing a possible
candidate for an additional VP22 binding partner. Furthermore,
as HSV-1 VP22 has been shown to bind to gD and PRV VP22
interacts with gM, it is possible that the C terminus of VP22
contains a gD and/or a gM binding site (4, 20).
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In the present study, we aimed to clarify the molecular
mechanism by which VP22 is recruited into the virus particle.
We show that HSV-1 VP22 binds efficiently to VP16, gE, and
gM in the infected cell, but we cannot detect an interaction
with gD. We show that the packaging domain of VP22 binds to
the cytoplasmic tail of gE but not gM and that the same region
of VP22 is recruited to the secretory pathway by gE in the
absence of other virus proteins. Finally, we show that a mutant
VP22 protein lacking a 14-residue peptide from its packaging
domain is unable to interact with gE during infection, exhibits
a different subcellular localization, and fails to assemble into
the virus particle. This is the first characterization of a single
protein-protein interaction essential for the packaging of an
HSV-1 tegument protein.
MATERIALS AND METHODS
Cells. Vero, BHK, COS-1, and MDBK cells were grown in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% newborn calf serum. Sf9 cells were
grown at 25°C in TC 100 medium (Gibco) supplemented with 10% heat-inacti-
vated fetal bovine serum.
Plasmids and viruses. Viruses were routinely grown in BHK cells or Vero cells
and titrated on Vero cells. Extracellular virions were purified on Ficoll gradients
from the infected cell medium of 5  108 BHK cells as described previously (17).
Infectious virus DNA was also produced from extracellular virus as described
previously (17). The parental virus strain used in this study was strain 17 of
HSV-1. The recombinant HSV-1 expressing green fluorescent protein (GFP)-
tagged VP22 (166v) has been described previously (17). The HSV-1 VP22 de-
letion mutant (169v) has also been described before (12). Plasmids expressing
GST fused to the C-terminal 106 residues of glycoprotein E (gE) and the
C-terminal 126 residues of gM were kindly provided by Colin Crump (Depart-
ment of Pathology, University of Cambridge). The expression vector for GST–
full-length VP16 was kindly provided by Peter O’Hare (Marie Curie Research
Institute, Oxted, Surrey, United Kingdom). Plasmids expressing gE and gM
under the control of the human cytomegalovirus (CMV) immediate-early pro-
moter were kindly provided by Helena Browne and Colin Crump, respectively
(Department of Pathology, University of Cambridge). Plasmid pGE155, express-
ing GFP-tagged VP22 under the control of the CMV immediate-early promoter,
has been described before (16). Plasmids pAM8, pAM17, pAM5, pGFP160-301,
pGE171, and pGE192, expressing residues 1 to 160, 1 to 212, 1 to 267, 160 to 301,
174 to 301, and 192 to 301 of VP22 as GFP fusion proteins, have been described
previously (26). Plasmid pGE197, expressing residues 1 to 226 of VP22 as a GFP
fusion protein, was constructed by PCR amplification of this region of VP22,
followed by insertion into pEGFPC1. Plasmid pGE198, expressing VP22 with a
deletion of residues 213 to 226, was generated by PCR amplification of residues
226 to 301 of VP22 as an NsiI/BglII fragment. This fragment was then inserted
into NsiI/BamHI-digested pUL49epB (35), generating a VP22 open reading
frame with an internal deletion of residues 213 to 226. This open reading frame
was then transferred to pEGFPC1 to generate a GFP fusion protein. To con-
struct plasmid pRC06, expressing GFP fused to VP22 with a deletion of residues
170 to 192, the region encoding residues 1 to 170 was amplified by PCR as a
BglII/HindIII fragment and inserted into BglII/HindIII-cut pGE192. Plasmid
pAM15, expressing GFP fused to VP22 with a deletion of residues 160 to 174,
was made in the same way by amplifying the region encoding residues 1 to 160
of VP22 by PCR and inserting this fragment into plasmid pGE171.
To transfer the 213-226 mutation into the virus, the VP22 open reading
frame from pGE198 was removed as a BamHI/BglII fragment and inserted into
the BamHI site of plasmid pEB1, which contains the GFP open reading frame
surrounded by the flanking sequences of VP22 gene UL49. This generated
plasmid pEB2. The gEbind virus was constructed by cotransfection of pEB2
and infectious 169vc DNA (a nonfluorescing variant of our original 22 virus)
into Vero cells, and the resulting green fluorescent recombinant virus was plaque
purified three times on the same cells before PCR analysis and sequencing of the
mutated region of the genome. The 170-192 mutation of VP22 was transferred
into the virus by inserting the BsrGI/NsiI fragment from pRC06 into BsrGI/NsiI-
cut plasmid pGE166. The recombinant virus (gEbind2) was then isolated as
described above for the gEbind virus.
For virus growth curves, MDBK cells grown in a six-well plate (1  106/well)
were infected at a multiplicity of 0.1 in 1 ml medium per well. After 1 h (taken
as 1 h postinfection), the inoculum was removed, the cells were washed with
phosphate-buffered saline (PBS), and 2 ml fresh medium was added to each well.
At a range of times after infection, one well of infected cells was harvested for
total virus yield and titrated on Vero cells. All plaque assays were carried out in
Dulbecco’s modified Eagle’s medium supplemented with 2% newborn calf serum
and 1% human serum (Harlan Sera-Lab).
To construct baculovirus for expression of full-length His-tagged VP22, the
VP22 open reading frame from plasmid pGE109 (18) was inserted as a BglII
fragment into the BglII site of plasmid pAcHLT-B (Pharmingen) and the result-
ing plasmid was cotransfected into Sf9 cells with Baculogold DNA (Pharmingen).
Recombinant baculovirus was further amplified to produce virus stocks for the
purification of His-VP22.
Expression and purification of His-tagged VP22 from baculovirus-infected Sf9
cells. Following preliminary characterization of His-VP22 expression from the
recombinant baculovirus, approximately 108 Sf9 cells were infected at a multi-
plicity of 5 and harvested 3 days later. A total cell extract was made by resus-
pension in 100 ml of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, 1% NP-40, 0.1% Triton X-100, protease inhibitors) for 10 min on ice.
After centrifugation for 20 min at 9,000  g in the cold, the supernatant was
retained and incubated with 2 ml of a 50% suspension of Ni-nitrilotriacetic acid
(NTA) beads (Qiagen) for 1 h at 4°C. After extensive washing in 50 mM
NaH2PO4–300 mM NaCl–20 mM imidazole–protease inhibitors, the beads were
transferred to a column and bound material was eluted with 500-l aliquots of 50
mM NaH2PO4–300 mM NaCl–250 mM imidazole–protease inhibitors. Samples
of each were analyzed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), followed by Coomassie blue staining, and those aliquots
that contained only His-VP22 were pooled.
Pulldown of infected cell extracts on His-tagged VP22. Approximately 2  108
Vero cells were infected with HSV-1 strain 17 at a multiplicity of 0.1, and a total
extract was made 48 h after infection by resuspension in 50 ml of lysis buffer (50
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 1% NP-40, 0.1% Triton X-100,
protease inhibitors) for 10 min on ice. After centrifugation for 20 min at 9,000 
g in the cold, the supernatant was precleared by incubation with 2 ml of a 50%
suspension of Ni-NTA beads for 1 h at 4°C. The precleared supernatant was then
incubated with 2 ml of Ni-NTA beads with bound, His-tagged VP22 for a further
hour at 4°C. The beads were washed twice in 50 mM NaH2PO4–300 mM
NaCl–20 mM–protease inhibitors, and bound material was eluted in 10 500-l
aliquots of 50 mM NaH2PO4–300 mM NaCl–250 mM imidazole–protease inhib-
itors.
Expression and purification of GST-tagged proteins. GST fusion proteins
were expressed in Escherichia coli strain BL21 by inducing a 250-ml culture with
1 mM isopropyl--D-thiogalactopyranoside (IPTG), followed by a further 3-h
incubation. The cells were then pelleted, resuspended in 10 ml PBS containing
protease inhibitors and 1 mg/ml lysozyme, and left on ice for 30 min. Following
sonication, Triton X-100 was added to 1% and the extracts were incubated for a
further 30 min rotating at 4°C and centrifuged at 4,000 g for 30 min at 4°C. The
soluble supernatant was added to 200 l of a 50:50 suspension of glutathione-
Sepharose beads and rotated for 1 h at 4°C, and unbound protein was washed off
the beads by three washes with PBS.
Pulldown of transfected cell extracts on GST-tagged proteins. COS-1 cells in
6-cm dishes were transfected with the relevant plasmids with Lipofectamine
(Invitrogen). Forty hours later, cells were washed with PBS and harvested in 1 ml
of lysis buffer (50 mM Tris [pH 7.5], 200 mM NaCl, 2 mM MgCl, 1% NP-40,
protease inhibitors). The samples were left on ice for 20 min and centrifuged at
12,000  g for 30 min at 4°C. A 400-l volume of supernatant was mixed with the
relevant GST fusion protein already bound to glutathione-Sepharose beads.
Following 2 to 3 h of rotation at 4°C, the beads were washed three times with lysis
buffer and samples of each were analyzed by SDS-PAGE and Western blotting.
Reagents and antibodies. Monoclonal antibodies to GFP and HSV-1 major
capsid protein VP5 were obtained from Clontech and Autogen Bioclear, respec-
tively. The monoclonal anti-VP16 (LP1) and anti-gD (LP14) antibodies and the
polyclonal anti-gM antibody were kindly provided by Helena Browne (Depart-
ment of Pathology, University of Cambridge). Anti-VP22 polyclonal antibodies
AGV031 and AV600 have been described previously (16). Monoclonal anti-gE
and anti-ICP0 (11060) antibodies were kindly provided by David C. Johnson
(Department of Molecular Microbiology and Immunology, Oregon Health Sci-
ences University, Portland) and Roger Everett (MRC Virology Unit, Glasgow,
Scotland), respectively. Anti-TGN46 antibody was obtained from Serotec.
SDS-PAGE. Protein samples were analyzed on 10 or 15% polyacrylamide gels
and electrophoresed in Tris-glycine buffer. Following electrophoresis, gels were
either stained with Coomassie blue or transferred to nitrocellulose for analysis by
Western blotting. Western blots were developed with an enhanced chemilumi-
nescence kit (Pierce).
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Immunofluorescence. Cells for immunofluorescence were grown on 16-mm
coverslips in individual wells of a six-well plate. Cells were fixed for 20 min in 4%
paraformaldehyde, permeabilized for 10 min in PBS containing 0.5% Triton
X-100, and blocked by incubation for 10 min in PBS containing 10% newborn
calf serum. Primary antibody was added for 15 min of incubation in the same
solution, and following extensive washing in PBS, the appropriate secondary
antibody (all from Vector Labs) was added in block solution and the mixture was
incubated for a further 10 min. The coverslips were then washed extensively in
PBS and mounted in Vectashield containing 4,6-diamidino-2-phenylindole
(DAPI; Vector Labs). Images were acquired with a Zeiss LSM410 or LSM510
confocal microscope. The resulting images were processed with Adobe Photo-
shop software.
Live cell fluorescence. Vero cells for fluorescence studies were grown in two-
well Lab-Tek coverglass chambers (Quadrachem Laboratories). Infections of
GFP-tagged viruses were carried out at a multiplicity of 5, and images were
subsequently acquired with a Zeiss LSM410 or LSM510 confocal microscope.
The resulting images were processed with Adobe Photoshop software.
Immunoprecipitation assay. Vero cells grown in 6-cm dishes were infected
with the relevant viruses at a multiplicity of 1. After 20 to 24 h, the cells were
washed twice with PBS, solubilized in 1 ml radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.1% SDS, 1% Na deoxy-
cholate, 1% NP-40), and incubated on ice for 20 min. The cells were then
centrifuged at 12,000  g for 30 min at 4°C, and the supernatant was collected.
The appropriate antibody was added to 400 l of lysate and incubated for 3 h at
4°C with rotation. Forty microliters of protein A-Sepharose beads was added, the
mixture was incubated for 4 h at 4°C with rotation, and the resulting protein
A-antibody complexes were washed five times with PBS. The immunoprecipi-
tated proteins were then analyzed by SDS-PAGE, followed by Western blotting.
Alternative immunoprecipitation assay. The alternative immunoprecipitation
assay was carried out as described by Chi and coworkers (4). Briefly, infected
cells were harvested in 50 mM Tris-HCl (pH 7.6)–150 mM NaCl–0.5% NP-40–
0.5 mM EDTA–2 mM dithiothreitol–protease inhibitors and incubated on ice for
30 min and then insoluble material was pelleted for 20 min at 13,000 g and 4°C.
The resulting lysates were precleared with protein A-Sepharose beads for 20 min
at 37°C and then incubated with fresh beads and the appropriate antibody for 15
min at 37°C. Following four washes with the lysis buffer, the bound material was
analyzed by SDS-PAGE and Western blotting.
RESULTS
HSV-1 VP22 binds to VP16, gE, and gM but not gD in
infected cells. HSV-1 VP22 has been reported to have a num-
ber of virus binding partners, namely, VP16, gE, and gD (4, 13,
19, 32, 33). In addition, PRV VP22 has been shown to interact
with the cytoplasmic tail of gM (20). To further characterize
the molecular interactions that HSV-1 VP22 exhibits during
infection, we carried out coimmunoprecipitation assays with
infected cells. Vero cells were infected with either the 22
virus, expressing GFP in place of VP22, or the GFP-VP22-
expressing virus at a multiplicity of 1 and harvested for immu-
noprecipitation 20 to 24 h after infection. Immunoprecipita-
tion was carried out with a polyclonal anti-GFP antibody, and
the resulting immunocomplexes were analyzed by SDS-PAGE,
followed by Western blotting with a range of antibodies (Fig.
1A). GFP and GFP-22 were efficiently precipitated from the
22- and GFP-22 infected cells, respectively, as demonstrated
by blotting with a GFP monoclonal antibody. As shown previ-
ously (23), VP16 was efficiently coprecipitated with GFP-22
but not GFP. Likewise, gE was coprecipitated in a VP22-
specific fashion. However, by contrast, there was no evidence
for the presence of gD in the precipitated protein complex.
Interestingly, gM was also seen to coprecipitate with VP22
but the levels of gM in the 22-infected cell extract were
undetectable, making it unclear whether this binding was spe-
cific for VP22 (Fig. 1A, gM). As these samples had been boiled
prior to analysis and gM is known to precipitate under these
conditions, we repeated the gM blot assay with samples that
were heated to only 56°C before being loaded onto the gel. In
this case, gM was detectable in both wild-type (WT)- and
22-infected cell extracts but the levels in 22 were somewhat
lower (Fig. 1B, Input). While trace amounts of gM protein
from the WT extract bound nonspecifically to beads in the
absence of antibody (Fig. 1B, no Ab), the level present in the
GFP-specific immunocomplexes was much greater (Fig. 1B,
GFP IP), confirming that gM had coprecipitated with VP22.
Furthermore, no gM was present in the immunoprecipitation
from 22-infected cells (Fig. 1B, GFP-IP), a result that was
reproduced in a later experiment (see Fig. 8F), where the gM
levels in the 22-infected cell input extract were higher than in
the experiment shown in Fig. 1. Taken together, these results
suggest that HSV-1 gM interacts with HSV-1 VP22 in the
infected cell.
The absence of gD after VP22 immunoprecipitation was an
unexpected result, as it has been reported by other groups that
these two proteins interact (4, 19). We repeated the experi-
ment with antibodies specific to both the N and C termini of
VP22 (AGV031 and AGV600, respectively) that are more
efficient at immunoprecipitating than the GFP polyclonal an-
tibody used above. However, no gD was detected in the pull-
down complexes with these antibodies (data not shown). To
determine if the inability to detect gD was due to the immu-
noprecipitation methodology used, we repeated the VP22 im-
munoprecipitation with antibody AGV031 from infected cells
by the method from the previous study by Chi and coworkers
(4). In addition, the reciprocal gD immunoprecipitation was
carried out, followed by blotting for VP22. In both cases, al-
though the target protein was efficiently precipitated, the pu-
tative partner protein was not detected (Fig. 1C). In a further
attempt to demonstrate VP22 binding to gD, we next used a
different method to detect VP22 binding proteins in infected
cells. Full-length polyhistidine-tagged VP22 purified from bac-
ulovirus-infected sf9 cells was bound to nickel beads and incu-
bated with an infected cell extract made from 2  108 Vero
cells infected with strain 17 of HSV-1. Following 1 h of incu-
bation at 4°C, the beads were washed extensively to remove
nonbinding proteins and then the resulting VP22-specific com-
plexes were eluted from the beads in 500-l fractions with 250
mM imidazole. These fractions were analyzed by SDS-PAGE,
followed by Coomassie blue staining (Fig. 1D), indicating that
at least one specific binding protein of around 65 kDa was
detectable by staining. Western blotting of fractions 2 and 3
revealed that the major 65-kDa copurifying protein was VP16,
while blotting for a second tegument protein, VP13/14, dem-
onstrated that the VP16 binding to His-tagged VP22 was spe-
cific in nature. Importantly, blotting for gD showed no evi-
dence of gD binding to VP22 in this assay. We conclude that in
our experiments, although we demonstrated VP16, gE, and
now gM interactions with VP22 during HSV-1 infection with
ease, no gD interaction was detectable.
VP22 binds to VP16, gE, and gM in vitro. It has been shown
previously that HSV-1 VP22 binds to the cytoplasmic tail of gE
while PRV VP22 binds to the cytoplasmic tails of gE and gM
(19, 20, 32). Therefore, to extend our observations on the
VP22-interacting proteins described above, we first expressed
and purified on glutathione-Sepharose beads the C-terminal
106 residues of gE, the C-terminal 126 residues of gM, and
5206 STYLIANOU ET AL. J. VIROL.
 o
n
 February 22, 2017 by UNIVERSITY O
F SURREY
http://jvi.asm.org/
D
ow
nloaded from
 
full-length VP16 as GST fusion proteins. Equivalent amounts
of these fusion proteins, together with unfused GST (Fig. 2A),
were next used in pulldown assays in a manner similar to that
described previously by O’Regan and coworkers (32). COS-1
cells were transfected with plasmids expressing GFP alone or
GFP-tagged VP22, and soluble extracts were prepared (Fig.
2B) and incubated with the GST fusion proteins bound to
beads. After extensive washing, the protein complexes bound
to the beads were solubilized and analyzed by SDS-PAGE,
followed by Western blotting with an anti-GFP monoclonal
FIG. 1. Binding partners of VP22 in infected cells. (A) RIPA extracts were made from Vero cells infected with HSV-1 expressing GFP-VP22
(Wt) or HSV-1 expressing GFP in place of VP22 (22), and immunoprecipitations were carried out with a polyclonal anti-GFP antibody. The
resulting immunocomplexes (IP) were analyzed by SDS-PAGE, followed by Western blotting with antibodies for GFP, VP16, gE, gD, and gM.
(B) Immunoprecipitations were carried out as for panel A, but samples in loading buffer were heated to 56°C rather than boiled before analysis
by SDS-PAGE, followed by Western blotting for gM. A control immunoprecipitation in the absence of antibody was also carried out (no Ab).
(C) Vero cells infected with strain 17 of HSV-1 were subjected to immunoprecipitation for VP22 and gD by the method of Chi and coworkers (4).
I, input; f/t, flowthrough; B, bound. NB: the presence of the f/t sample on these gels has distorted the appearance of some bands. (D) Polyhistidine-
tagged VP22 purified from baculovirus-infected Sf9 cells was bound to Ni-NTA beads and incubated for 1 h with a precleared cell extract from
108 strain 17-infected Vero cells. The beads were washed twice, and then bound material was eluted in 500-l aliquots. Samples were analyzed by
SDS-PAGE, followed by Coomassie blue staining. f/t, flowthrough; p/c, precleared extract. The asterisk denotes the major 65-kDa VP22 binding
protein.(E) Samples of the input extract and eluates 2 and 3 (E2 and E3) were analyzed by Western blotting with antibodies for VP16, VP13/14,
gD, and actin. The values on the left are molecular sizes in kilodaltons.
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antibody. While GFP alone showed no binding activity to any
of the fusion proteins, GFP-VP22 interacted efficiently with
GST-gE and GST-VP16 but not GST alone (Fig. 2C), as de-
scribed previously by others (32, 33). Interestingly, GFP-22
also bound, but more weakly, to the C-terminal tail of gM. To
ensure that these results were not simply due to nonspecific
stickiness of the glycoprotein tails, we used a GFP-tagged ver-
sion of tegument protein VP13/14 in the same assay (Fig. 2D).
In this case, GFP-13/14 bound efficiently to GST-VP16, a re-
sult that confirms and extends our previous finding that
VP13/14 interacts with VP16 in coimmunoprecipitation studies
of infected cells (11). However, VP13/14 showed little binding
to gE, indicating that the VP22 interaction with gE is specific.
Moreover, VP13/14 bound efficiently to gM, hinting at an ad-
ditional, as-yet-undescribed, tegument/envelope interaction.
The C terminus of VP22 contains a 93-residue gE binding
domain. To investigate the region of VP22 involved in binding
to these proteins, we expressed a range of GFP-tagged N- and
C-terminal truncations of VP22 in COS-1 cells and tested them
in our GST pulldown assays (Fig. 3A). The N-terminal 160
residues of VP22 showed no binding to GST-gE, while the
C-terminal 140 residues bound as efficiently as the full-length
protein, placing the gE binding domain in this C-terminal
region of VP22 (Fig. 3B, compare GFP 1-160 with GFP 160-
301). This is in agreement with the studies by O’Regan and
coworkers (32). To refine the N-terminal limit of the gE bind-
ing domain, we then used a number of mutants with larger
N-terminal truncations (Fig. 3A). Residues 174 to 301 bound
to gE as efficiently as residues 160 to 301 (Fig. 3B, GFP 174-
301, but a further truncation of 18 residues from the N termi-
nus abolished the VP22-gE interaction (Fig. 3B, GFP 192-301).
Hence, we can place the N-terminal limit of the gE binding
domain of VP22 at residue 174 of the protein. The C-terminal
limit of the gE binding domain was determined by using C-
terminal truncation mutants expressing residues 1 to 212, 1 to
226, and 1 to 267, respectively. Of these three proteins, only
the largest (residues 1 to 267) was able to bind to GST-gE in
the pulldown assay (Fig. 3B), thereby placing the gE binding
domain of VP22 within residues 174 to 267 of the protein.
gE recruits VP22 to the Golgi region of transfected cells.
When VP22 is expressed in isolation by transient transfection,
it localizes to cellular microtubules, which it reorganizes into
characteristic bundles, a property that is maintained in the
GFP-tagged variant (14, 15). By contrast, gE is reported to
localize to the trans-Golgi network (TGN) in both virus infec-
tion and transient transfection (1, 27). Thus, we wished to
determine the effect of coexpressing gE with VP22 on the
localization of the two proteins. We first assessed the subcel-
lular localization of gE in our assays by transfection of Vero
cells, followed by immunofluorescence assays with both an-
ti-gE and anti-TGN46 antibodies. As described by others (1),
gE localized to a perinuclear site where it colocalized with the
TGN marker TGN46 (Fig. 4, TGN, gE). We next transfected
Vero cells with full-length GFP-VP22 and a range of the trun-
cated fusions described above either with or without gE. We
have described the localization of these GFP-tagged mutant
VP22 proteins in a previous paper (26). As we have previously
shown, GFP-VP22 localized in a striking cytoplasmic filamen-
tous pattern that is representative of reorganized microtubules
(Fig. 4, 1-301, gE). However, in the presence of gE, VP22
localization was dramatically altered to colocalization with gE
in the Golgi region of the cell (Fig. 4, 1-301, gE). Moreover,
although the residue 174 to 301 mutant VP22 protein had lost
the ability to reorganize microtubules (Fig. 4, 174-301, gE),
in the presence of gE this protein was also recruited to the
Golgi region (Fig. 4, 174-301,gE). By contrast, the 192 to 301
mutant VP22 protein exhibited the same cytoplasmic localiza-
tion in the absence and presence of gE, indicating that these
FIG. 2. In vitro binding of VP22 partners. (A) GST and GST fused
to full-length VP16, the cytoplasmic tail of gE, or the cytoplasmic tail
of gM were expressed and purified from E. coli strain BL21 and
analyzed by SDS-PAGE, followed by Coomassie blue staining.
(B) COS-1 cells were transfected with plasmids expressing GFP or
GFP fused to full-length VP22, and soluble extracts were made and
analyzed by SDS-PAGE, followed by Western blotting for GFP.
(C) The extracts from panel B were incubated for 1 h with the GST
fusion proteins shown in panel A that were already bound to glutathi-
one-Sepharose beads. After extensive washing, the bound proteins
were analyzed by SDS-PAGE, followed by Western blotting for GFP.
(D) COS-1 cells were transfected with a plasmid expressing GFP fused
to full-length VP13/14, and a soluble extract was made and analyzed
for binding to the GST fusion proteins shown in panel A as described
for panel C. The values on the left of panels A and B are molecular
sizes in kilodaltons.
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two proteins did not interact (Fig. 4, 192-301). These results
are in agreement with the binding studies described above.
Likewise, when the plasmids expressing the GFP-tagged C-
terminal truncations expressing residues 1 to 212 and 1 to 267
of VP22 were cotransfected with gE, only the residue 1 to 267
variant was relocalized to the Golgi region of the cell (Fig. 4,
compare 1-267 with 1-212). Hence, recruitment of the VP22
variants to the Golgi region by gE correlated directly with their
ability to interact in vitro.
Characterization of the VP22-gM interaction. We next com-
pared the nature of the VP22-gM interaction with that of the
VP22-gE interaction by using GST pulldown assays of the
VP22 truncation mutant proteins on the gM cytoplasmic tail.
The results confirm that full-length VP22 is able to bind to the
cytoplasmic tail of gM (Fig. 5A, 1-301). However, in contrast to
gE, we were unable to define a minimal gM binding domain
within VP22 that retained optimal binding, as every truncation
mutant protein examined was greatly reduced in its ability to
FIG. 3. gE binds to the packaging domain of VP22. (A) Line drawings of the N- and C-terminal truncation mutant forms of VP22 used in this
study. (B) COS-1 cells were transfected with plasmids expressing each of the GFP-tagged mutant forms of VP22 shown in panel A, and soluble
extracts were tested for the ability to bind GST or GST fused to the cytoplasmic tail of gE as described for Fig. 2C. The values on the left are
molecular sizes in kilodaltons.
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bind gM (Fig. 5A and B). To determine if gM was able to
recruit full-length VP22 to the secretory pathway in the same
manner as gE, we next cotransfected Vero cells with plasmids
expressing gM and GFP-VP22 and carried out immunofluo-
rescence studies as described above. As expected, gM ex-
pressed alone localized to the Golgi/TGN region of the cell
(Fig. 6A, gM alone). In contrast to coexpression of VP22 with
gE, coexpression with gM had little effect on the microtubule
pattern of VP22 and there was no evidence of colocalization of
the two proteins (Fig. 6A, 1-301). While the gM pattern was
relatively fragmented in the presence of VP22, we believe this
is due to a general fragmentation of the secretory pathway
induced by the VP22-specific microtubule reorganization. To
confirm this, we expressed CFP-VP22 in Vero cells stably ex-
pressing a yellow fluorescent protein-Golgi body marker and
showed extensive fragmentation of the Golgi body in compar-
ison to that in untransfected cells (Fig. 6B). Finally, we coex-
pressed gM with a number of the truncation mutant VP22
proteins that retain reduced gM binding but saw no evidence of
colocalization of these proteins that might indicate interaction
(Fig. 6A, 1-212 and 160-301). Hence, we conclude that
although we can demonstrate full-length VP22 binding to gM
by using biochemical assays, this interaction is not reproduced
in cotransfected cells in the same way as the gE interaction and
that gM is unlikely to be an efficient direct binding partner of
VP22 in the cellular environment.
A deletion of 14 residues from the gE binding domain abol-
ishes VP22 interaction with gE. We next wished to construct a
VP22 variant that was unable to bind gE by deleting as short a
region as possible in the 93-residue gE binding domain of
full-length VP22. Three internal deletions were introduced
into the construct expressing GFP-VP22—two within the gE
binding domain (170-192 and 213-226) and one just outside
(160-172) (Fig. 7A). These mutant proteins were tested in
GST pulldown assays on the gE cytoplasmic tail as before,
revealing that both mutations internal to the gE binding do-
main abolished gE binding (Fig. 7B). By contrast, the third
mutation, which lies outside the gE binding domain, had no
effect on the interaction, confirming that the results for the first
two mutant proteins represent specific inhibition of the
VP22-gE complex (Fig. 7B).
Mutation of the VP22 gE binding domain in HSV-1. We next
addressed the role played by the VP22-gE interaction in virus
infection by introducing the smallest mutation that we had
identified to abolish gE binding by VP22, namely, 213-226
(now called gEbind). To construct a recombinant HSV-1
expressing VP22 gEbind in place of WT VP22, we first con-
structed a transfer plasmid expressing this open reading frame
as a GFP fusion protein, surrounded by its natural flanking
sequences from the HSV-1 UL49 gene. This plasmid was co-
transfected into Vero cells with infectious DNA from our pre-
viously described HSV-1 VP22 deletion mutant (22) (12),
and green fluorescent plaques were isolated and purified three
times before characterization of the resulting virus. Conse-
quently, we generated a virus expressing GFP-tagged VP22
(gEbind) that could be analyzed next to our viruses express-
ing GFP-tagged full-length VP22 (WT) (17) and GFP in place
of VP22 (22) (Fig. 8A). In the same way, we also constructed
FIG. 4. gE recruits the packaging domain of VP22 to the secretory pathway. Vero cells grown on coverslips were transfected with plasmids
expressing the denoted regions of VP22 as GFP fusion proteins (green) either in the absence or in the presence of a plasmid expressing gE. Twenty
hours after transfection, cells were fixed with 4% paraformaldehyde and an immunofluorescence assay was carried out with the anti-gE antibody
(red). Nuclei were stained with DAPI (blue). TGN denotes Vero cells processed for immunofluorescence with the anti-TGN 46 antibody.
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a second virus containing the 170-192 deletion described
above, which was also shown to abolish the gE-VP22 interac-
tion (gEbind2 in Fig. 8A).
To assess the VP22 expression of the gEbind virus, mono-
layers of Vero cells were infected at a multiplicity of 5 with
recombinant HSV-1 expressing either full-length GFP-VP22
or GFP-gEbind and harvested at various times after infec-
tion. Samples from each time point were then analyzed by
Western blotting with a monoclonal anti-GFP antibody, which
indicated that the GFP-gEbind protein expressed during in-
fection was the correct size and was expressed at the same time
and to the same levels as full-length GFP-VP22 (Fig. 8B,
GFP). In addition, a blot for the tegument protein VP16 indi-
cated that this second viral protein was also expressed at equiv-
alent levels in both infections (Fig. 8B, VP16). We next used
these viruses in the same GST pulldown assays that we had
performed with transfected cell extracts. Vero cells were in-
fected with viruses expressing either full-length GFP-VP22
(WT), mutant GFP-VP22 (gEbind), or no VP22 (22) and
harvested 16 h after infection. Soluble extracts were incubated
with GST-gE, GST-gM, or GST-VP16 bound to glutathione-
Sepharose beads as before, and the resulting complexes were
analyzed by SDS-PAGE, followed by Western blotting with the
anti-GFP antibody (Fig. 8C). In this case, while the WT GFP-
FIG. 5. gM binding to VP22. (A) COS-1 cells were transfected with plasmids expressing each of the GFP tagged mutant forms of VP22 shown
in Fig. 3A, and soluble extracts were tested for the ability to bind GST fused to the cytoplasmic tail of gM as described for Fig. 2C. The values
on the left are molecular sizes in kilodaltons. (B) Summary of the results shown in panel A. / denotes binding that is greatly reduced compared
to that of full-length VP22.
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tagged VP22 protein bound efficiently to all three GST fusion
proteins, the gEbind protein bound only to GST-VP16.
To confirm that this mutant form of VP22 was unable to
interact with gE within infected cells, extracts of infected cells
were prepared in RIPA buffer and immunoprecipitations were
carried out with a polyclonal anti-GFP antibody. The resulting
purified complexes were analyzed by Western blotting with a
monoclonal anti-GFP antibody to determine the efficiency of
immunoprecipitation and with an antibody against gE to assess
the VP22-gE interaction. Although the three GFP fusion pro-
teins were precipitated by the GFP antibody with equal effi-
ciency (Fig. 8D, GFP), only the full-length protein was able to
coprecipitate gE (Fig. 8D, gE), confirming that the 14 residues
between 213 and 226 of VP22 are required for gE binding in
infection. Blotting of these immunoprecipitations for gD fur-
ther confirmed that this glycoprotein does not interact with
VP22 under these conditions. We next wished to determine if
the gEbind mutant form of VP22 retained its ability to inter-
act with VP16 in infected cells. In this case, VP22 was immu-
noprecipitated from infected cells with a polyclonal anti-VP22
antibody and the resulting complexes were blotted for GFP
and VP16 to determine the level of VP16 that had coprecipi-
tated with VP22. The full-length and gEbind mutant proteins
were both precipitated by the VP22 antibody with equal effi-
ciency (Fig. 8E, VP22). In addition, VP16 also coimmunopre-
cipitated equally with both forms of VP22 but was not present
in the sample immunoprecipitated from 22-infected cells
(Fig. 8E), confirming that the gEbind mutant form of VP22
retains its ability to interact with its tegument protein partner,
VP16, in infected cells.
In the process of these studies, we generated a second mu-
tant virus expressing GFP-VP22 lacking residues 170 to 192
(gEbind2 in Fig. 8A), which we had shown in our transfected
cell assays to be unable to bind to the cytoplasmic tail of gE
(Fig. 7B). Hence, we used this virus in coimmunoprecipitation
assays with infected cells to provide further evidence that we
had truly identified gE binding mutant proteins in our GST
pulldown assays. VP22 was immunoprecipitated from infected
cell extracts as before with a polyclonal anti-GFP antibody, and
the resulting immunocomplexes were analyzed by Western
blotting with an antibody against GFP, showing that all of the
immunoprecipitations had worked efficiently (Fig. 8F, GFP).
Western blotting with the gE antibody revealed that although
all of the extracts contained high levels of gE, only full-length
VP22 was able to coprecipitate the glycoprotein (Fig. 8F, gE),
confirming that our second gE binding mutation virus (gE-
bind2) was unable to interact with gE in the infected cell.
Interestingly, blotting of these immunoprecipitations for gM
showed that the gEbind mutant form of VP22 was unable to
complex with gM while the gEbind2 mutant form appeared
to coimmunoprecipitate a lower level of gM than the WT
protein (Fig. 8F). By contrast, immunoprecipitations carried
out with a VP22 polyclonal antibody and analyzed by Western
blotting with a VP16 antibody indicated that all of the variants
of VP22 were able to interact with VP16 (Fig. 8G, VP16).
The gEbind mutant form of VP22 exhibits aberrant local-
ization in infected cells. Vero cells infected with HSV-1 ex-
pressing GFP-tagged VP22 exhibit a characteristic fluores-
cence pattern at around 8 h postinfection in which VP22
localizes to numerous small complexes that are often clustered
close to the nucleus (Fig. 9A, WT). We have previously pro-
vided evidence to suggest that localization of VP22 to these
complexes correlates with efficient assembly of VP22 into the
virus structure (23). Hence, to determine the effect of abolish-
ing gE binding on VP22 localization to these complexes, we
next determined the localization of GFP-VP22 gEbind in
Vero cells infected in the same manner and imaged 8 h after
infection. Strikingly, GFP-VP22 lacking gE binding localized
quite differently to WT GFP-VP22, with the mutant protein
exhibiting a predominantly diffuse cytoplasmic localization
(Fig. 9A, gEbind). Unlike WT GFP-VP22, which eventually
concentrates in the periphery of the infected cell at later times,
the localization pattern of the mutant varied little as infection
progressed (data not shown).
To assess the localization of VP22 in relation to gE in cells
infected with these viruses, Vero cells at the same stage of
infection were fixed and an immunofluorescence assay was
FIG. 6. gM does not alter the localization of VP22. (A) Vero cells
grown on coverslips were transfected with plasmids expressing gM
(red) and the denoted regions of VP22 as GFP fusion proteins (green).
Twenty hours after transfection, cells were fixed with 4% paraformal-
dehyde and an immunofluorescence assay was carried out with the
anti-gM antibody. Nuclei were stained with DAPI (blue). (B) A Vero
cell line stably expressing a yellow fluorescent protein-tagged Golgi
marker (red) was transfected with plasmid expressing GFP-tagged
full-length VP22 (green) and examined by live cell fluorescence.
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carried out with the anti-gE antibody. In WT-infected cells, it
is clear that GFP-VP22 and gE are colocalized in large parts of
the cell, particularly around the Golgi/TGN region (Fig. 9B,
WT). By contrast, there is no overlap between GFP-VP22 and
gE in the gEbind-infected cells, correlating with the inability
of this mutant to interact with gE (Fig. 9B, gEbind). It is also
noteworthy that although gE clearly localizes to the nuclear
membrane of WT-infected cells, VP22 does not colocalize with
gE at that site, suggesting that this population of gE is in some
way different from that in the Golgi/TGN region.
Characterization of virions produced from virus expressing
the gEbind mutant form of VP22. We next wished to deter-
mine if the gEbind mutant form of VP22 was capable of
being assembled into virions. To determine if the incorpora-
tion of GFP-VP22 is affected by the gEbind mutation, we
analyzed extracellular virions from viruses expressing full-
length or gEbind mutant VP22 by SDS-PAGE, followed by
Coomassie blue staining, with equal amounts of the virion
preparations loaded according to their major capsid protein
(VP5) content. The stained virion profiles show that while
full-length GFP-22 is discernible in these virions (Fig. 10A,
arrowed band), no equivalent band of the correct size for the
gEbind mutant protein was detected in virions produced by the
mutant virus. To confirm that this protein is reduced in content
in these virions, we next conducted Western blot assays with
the same amount of each preparation. Blotting for VP5
showed that the virions were approximately equally loaded
(Fig. 10B). However, blotting with antibodies against GFP
clearly indicated that there were minimal levels of GFP-VP22
present in the gEbind virions compared to that of the WT
virions (Fig. 10B). Thus, deletion of only 14 residues from the
VP22 open reading frame has a dramatic effect on both the
localization and assembly of VP22 into the virus particle, sug-
gesting that gEbind is a major determinant of VP22 recruit-
ment to the virus. Furthermore, a similar reduction in VP22
content was observed in gEbind2 virions (Fig. 10C). Finally,
because we have shown previously that VP22 is required for
the packaging of ICP0 into the virus tegument (12), we carried
out Western blotting to detect the level of ICP0 present in the
WT and gEbind virions. Consistent with our previous results,
this blot indicates that while ICP0 is easily detectable in WT
virions, no ICP0 is present in gEbind mutant virions, which
package greatly reduced levels of VP22 (Fig. 10B, ICP0).
We have previously shown that HSV-1 lacking the VP22
open reading frame exhibits a cell-specific replication defect in
epithelial MDBK cells (12). We have also shown that this
defect can be rescued by both WT VP22 and a variant of VP22
in which all of the phosphorylation sites have been mutated
(12, 36). Therefore, we next wished to determine if introduc-
tion of the gEbind mutant form of VP22 into the 22 virus was
also capable of rescuing this replication defect. Monolayers of
confluent MDBK cells were infected at a low multiplicity with
HSV-1 expressing either the full-length or the gEbind mutant
protein or with virus lacking the VP22 gene (22), and total
virus was harvested at a range of times after infection. The
resulting samples were titrated on Vero cells to determine the
efficiency of virus replication in MDBK cells (Fig. 10D). In
agreement with our previous results, there was a clear replica-
FIG. 7. Internal mutations within the gE binding domain of VP22 abrogate gE binding in vitro. (A) Line drawings of the three internal deletion
mutant forms of VP22 constructed. (B) A plasmid expressing each of these mutants as GFP fusion proteins was transfected into COS-1 cells and
analyzed for binding to GST and GST fused to the cytoplasmic tail of gE as described for Fig. 2C. The values on the left are molecular sizes in
kilodaltons.
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tion defect of the 22 virus compared to the WT virus in this
experiment. Interestingly, the virus expressing the gEbind
mutant form of VP22 also replicated poorly in MDBK cells
compared to the WT virus, a result that was highly reproduc-
ible (Fig. 10E). Taken together, these results suggest that a
deletion of only 14 residues from the VP22 open reading frame
is sufficient to mimic a complete deletion of the gene in virus
replication in MDBK cells.
DISCUSSION
A major aim in the field of herpesvirus assembly is to un-
derstand the molecular mechanisms involved in recruiting the
large number of virus-encoded proteins that end up in the
tegument of the virus particle. Several potential recruitment
strategies could be used in the process of virus tegumentation,
including passive acquisition of proteins that happen to be in
the vicinity of the assembly site, targeting by interaction with
specific cellular proteins, or recruitment to assembling parti-
cles by protein-protein interactions with other virus proteins.
In recent years, there have been a number of reports that
support the latter strategy as the mechanism for tegument
protein packaging (see below), but no single protein-protein
interaction has been proven to be required for a tegument
protein to be packaged.
The molecular events involved in tegumentation have been
previously investigated by using a range of techniques to search
for relevant protein-protein interactions. For example, the
PRV UL36 protein has been shown to interact with an outer
capsid protein, UL25, providing evidence for a position for
UL36 close to the capsid (5). Yeast two-hybrid studies have
revealed a list of potential tegument-tegument interactions
that may be involved in the recruitment of the other tegument
proteins, although the significance of many of these has not yet
been explored in the context of virus infection (42). In addi-
tion, pulldown experiments with the cytoplasmic tails of a num-
ber of HSV-1 glycoproteins have shown interactions between
tegument proteins and envelope proteins such as VP16-gH,
VP22-gD, VP22-gE, UL11-gD, and UL11-gE (4, 19, 22, 32).
Nonetheless, none of these interactions has been shown to be
crucial for tegument protein recruitment and it has been sug-
gested that redundancy may exist among tegument/envelope
interactions.
Our aim in the present study was to dissect the molecular
interaction(s) involved in the recruitment of HSV-1 VP22 into
the virus particle. VP22 is not absolutely essential for HSV-1
FIG. 8. Small mutations within the gE binding domain of VP22 inhibit the VP22-gE interaction in infected cells. (A) Line drawings of the
viruses used in this study. gEbind and gEbind2 represent the 213-226 and 170-192 mutations shown in Fig. 7, respectively. (B) Vero cells were
infected with HSV-1 expressing WT GFP-VP22 or GFP-VP22 (gEbind) at a multiplicity of 2, and total extracts were obtained at various times
after infection. These samples were analyzed by SDS-PAGE, followed by Western blotting with antibodies against GFP and VP16. (C) Soluble
extracts were made from Vero cells infected with the 22, WT, or gEbind virus and used in binding assays with GST fused to the cytoplasmic
tail of gE, the cytoplasmic tail of gM, or full-length VP16 as described for Fig. 2C. (D) Immunoprecipitations were carried out with the polyclonal
GFP antibody on RIPA extracts of cells infected with the 22, WT, or gEbind virus, and the resulting immunocomplexes were analyzed by
Western blotting with antibodies against GFP, gE, and gD. (E) Immunoprecipitations were carried out as for panel D but with the polyclonal
anti-VP22 antibody AGV031. The resulting immunocomplexes were analyzed by Western blotting with antibodies against GFP and VP16.
(F) Immunoprecipitations were carried out with the polyclonal GFP antibody on RIPA extracts of cells infected with the 22, WT, gEbind, or
gEbind2 virus, and the resulting immunocomplexes were analyzed by Western blotting with antibodies against GFP, gE, and gM. Nonspecific
refers to cross-reacting species that appeared in all pulldown lanes with a molecular weight higher than that of gM. (G) Immunoprecipitation assays
were carried out as for panel F but with the polyclonal anti-VP22 antibody AGV031. The resulting immunocomplexes were analyzed by Western
blotting with antibodies against GFP and VP16. The values on the left of panels C to F are molecular sizes in kilodaltons.
FIG. 9. VP22 colocalization with gE in infected cells is specific to its gE interaction domain. (A) Vero cells were infected with HSV-1 expressing
GFP-22 or GFP-gEbind at a multiplicity of 5 and examined live by fluorescence microscopy 8 h after infection. (B) Vero cells were infected with
HSV-1 expressing GFP-22 or GFP-gEbind at a multiplicity of 5 and fixed with 4% paraformaldehyde 8 h after infection. An immunofluorescence
assay was carried out with the anti-gE antibody (red), and nuclei were stained with DAPI (blue).
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growth in cell culture (12), and hence it is possible to introduce
mutations into the protein and determine the effect on levels
packaged into the tegument. In this way, we have previously
shown that while the N-terminal half of the protein is dispens-
able for VP22 assembly, the C-terminal half is absolutely re-
quired, suggesting that the C terminus contains a virus pack-
aging signal (23). This region of VP22 has been shown to
contain both a VP16 and a gE binding domain (23, 32, 33). Our
starting position was to revisit the population of VP22 binding
proteins present in the infected cell by using coimmunopre-
cipitation assays, whereby we demonstrated VP16 and gE in-
teraction with ease. Furthermore, in line with data from PRV,
we also showed an interaction between VP22 and gM that had
not yet been characterized in HSV-1 infection (20). However,
unlike two other groups, we were unable to demonstrate an
interaction with gD by using three different methods, and
therefore we suggest that if the VP22-gD interaction exists, it
is by nature extremely weak compared to the interactions with
VP16, gE, and gM.
According to our GST-gE pulldown assays, the gE binding
domain is present within residues 174 to 267 of VP22, con-
firming and refining the previously defined gE binding domain
of VP22 (32). Interestingly, coexpression of gE with the C-
terminal half of VP22 by transient transfection resulted in gE
recruiting VP22 to the Golgi region of the cell, suggesting that
gE is sufficient to recruit VP22 to cellular membranes. This
relocalization occurs even in the case of full-length VP22,
which localizes to microtubules when expressed in isolation,
implying that gE is the dominant partner in this relationship.
Taken together, these results show that the C-terminal pack-
aging domain of VP22 is sufficient for gE interaction and
recruitment to the secretory pathway. We were able to abro-
gate the VP22-gE interaction by introducing a small 14-residue
deletion into the gE binding domain and subsequently intro-
duced this small mutation into the virus to address the role of
gE binding in VP22 packaging into the virus. Characterization
of this and a second virus with a different mutation in this
region showed that gE binding correlated with the localization
of VP22 within the cell and its recruitment to the virus tegu-
ment. Taken together, these results explain our previous data
FIG. 10. VP22 is recruited to the HSV-1 virion by its interaction with gE. (A) Extracellular virions were purified from BHK cells infected with
HSV-1 expressing GFP-VP22 or GFP-gEbind and analyzed by SDS-PAGE, followed by Coomassie blue staining. (B) The same extracellular
virions shown in panel A were analyzed by Western blotting with antibodies against the major capsid protein VP5, GFP, gE, VP16, and ICP0.
(C) Extracellular virions were purified from BHK cells infected with HSV-1 expressing GFP-VP22 or GFP-gEbind2 and analyzed by SDS-PAGE,
followed by Western blotting with antibodies against the major capsid protein VP5, VP22, and VP16. (D) MDBK cells were infected with the 22,
WT, or gEbind virus at a multiplicity of 0.1, and total samples were taken up to 48 h after infection. Samples were titrated on Vero cells.
(E) MDBK cells were infected as for panel D, but samples were taken only at 48 h after infection. This experiment was carried out in triplicate.
The values on the left of panel A are molecular sizes in kilodaltons.
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on viruses expressing truncation mutant forms of VP22, where
we showed that any mutant expressing a shorter C-terminal
region than 160 to 301 was unable to localize to trafficking
complexes or assemble efficiently into the virus (23). At that
time, we interpreted this as a dependence on VP16, as the
binding domain for VP16 is also present in the C-terminal half
of VP22. However, it is clear from our present studies that
none of the viruses we used in that study would have separated
VP16 binding from gE binding. By contrast, the two gE binding
mutant proteins we have constructed in this study are still able
to interact with VP16 and yet are not packaged into the virus,
suggesting that gE binding is absolutely required. While we
cannot rule out an additional requirement for VP16 binding in
VP22 assembly from our own studies, as we do not yet have a
virus expressing a VP22 variant that binds gE but not VP16,
O’Regan and coworkers have concluded that VP16 is not re-
quired for VP22 assembly into the virion (33).
Our coimmunoprecipitation studies with infected cells im-
plicated gM as another potential partner in VP22 recruitment
to the virus. However, it is possible that the gM present in
these VP22-specific immunocomplexes does not interact di-
rectly with VP22 but precipitates with a VP22 binding partner.
In support of this, although we could demonstrate an interac-
tion between full-length VP22 and the cytoplasmic tail of gM
in our pulldown assays, this interaction did not map to the
VP22 packaging domain but seemed to require the full-length
protein for optimal interaction. Furthermore, this interaction
did not result in a relocalization of either protein in cotrans-
fected cells. In addition, in cells infected with our second mu-
tant virus, gEbind2, VP22 was able to at least partially inter-
act with gM in coimmunoprecipitations while not being
recruited to the virion. Hence, we conclude that the VP22-gM
interaction is unlikely to have a role in VP22 packaging.
Although the tegument was originally described as an amor-
phous layer, it now seems as if it may be a more ordered
structure and that tegument proteins may be added sequen-
tially to the capsid as it progresses through its maturation
pathway (29). Furthermore, tegument proteins have been di-
vided into inner and outer components by some workers, ac-
cording to the ease with which they can be biochemically re-
moved from the purified virus particle, with the assumption
that inner components (the hardest to extract) would be the
first to be recruited during assembly while the outer compo-
nents would be the last to be added in the maturation pathway
(43). Morphogenesis studies with viruses lacking individual
essential tegument proteins have also been used to define the
order of tegument protein incorporation, depending on the
stage at which virus morphogenesis is blocked. For example, in
the case of PRV and HSV-1 UL36 and UL37 gene mutants,
morphogenesis has been shown to be blocked at early stages in
the cytoplasm, thereby defining these two proteins as the in-
nermost tegument proteins (8, 9, 21, 25). Our results obtained
with cotransfected and infected cells suggest that gE recruits
VP22 to the cytoplasmic face of membranes within the Golgi
region of the cell. Because gE has been previously character-
ized to reside in the TGN in both infected cells and transfected
cells, we therefore suggest that gE recruits VP22 to the cyto-
plasmic side of the TGN. This is in agreement with previous
studies that indicate the TGN and/or endosomal membranes
as the site of final virus envelopment (10, 24, 41). Nonetheless,
because the Golgi and TGN compartments are closely associ-
ated in the cell, it is difficult to differentiate between them by
using cell markers in immunofluorescence alone, and further
studies are required to determine if VP22 first associates with
gE in the Golgi body or in the TGN.
One question that remains to be answered is whether the
population of VP22 that is recruited by gE is already part of
the assembling capsid at the time that it encounters the cyto-
plasmic tail of gE. The fact that the two proteins are seen to
colocalize as early as 6 h after infection might suggest that the
VP22-gE interaction occurs before the majority of capsids have
entered the maturation pathway. Furthermore, it has recently
been shown that the inner tegument protein UL37 localizes to
the Golgi region of the cell in the absence of capsid structures
but in a UL36-specific fashion, implying that even the inner-
most proteins in the tegument may be targeted to the envel-
opment site without prior association with capsids (7). It is also
of note that although gE is present within the nuclear mem-
brane, as well as the Golgi region, VP22 is not recruited to the
nuclear rim during infection, suggesting that the two popula-
tions of gE may differ. Interestingly, only the faster migrating
species of gE present in the infected cell appeared to coimmu-
noprecipitate with VP22 (Fig. 1A), suggesting that VP22 can
discriminate between different forms of gE due to, for exam-
ple, differential glycosylation or phosphorylation of gE (30, 34).
The growth phenotype of our gEbind mutant virus that
lacks only 14 amino acids of VP22 is equivalent to that of our
VP22 knockout virus (12), whereby both viruses produce small
plaques and show a replication defect in epithelial cells. This
suggests that the phenotype of the VP22 knockout virus is
primarily due to the absence of VP22 in the infecting virion
rather than the lack of VP22 expression throughout infection.
As both mutant viruses also fail to package the immediate-
early protein ICP0, which we have shown to be assembled in a
VP22-dependent fashion, it is possible that the phenotype may
be explained in part by the absence of ICP0 in the incoming
virions. Interestingly, the phenotype of an HSV-1 gE knockout
virus is also poor spreading in epithelial cells (2, 10) and as our
results predict that a gE mutant virus would not package
VP22 or ICP0, the gE mutant virus phenotype may also be
related in part to the absence of VP22 and/or ICP0 from the
virion. Finally, it is of note that, in the cases of Marek’s disease
virus and varicella zoster virus, both gE and VP22 are abso-
lutely essential for virus spreading (31, 39). Unlike HSV-1 or
PRV, these viruses do not release free virus but remain cell
associated and are entirely dependent on direct cell-to-cell
spreading to infect neighboring cells. Hence, the phenotypes
that we observe for gE and VP22 mutants of HSV-1 represent
the less extreme end of the spectrum of requirement for gE-
VP22 activities in alphaherpesvirus infection and may help
define a unifying role for these proteins across the alphaher-
pesviruses.
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